CHRM1 and prostate cancer: Among them, Fatty Acid Synthase (FASN) exhibited the best diagnostic performance in the TCGA validation cohort (AUC = 0.800), outperforming PTGS2 (0.783), ENPP2 (0.621), and CHRM1 (0.605), and was significantly overexpressed in prostate cancer tissues (|log2FC| > 1, adjusted P < 0.05).